Vor Biopharma Inc

Vor Biopharma Inc a clinicalstage company develops engineered hematopoietic stem cell eHSC therapies for cancer patients It is developing VOR33 an eHSC product candidate that is in phase 12 to treat acute myeloid leukemia AML and other hematological malignancies The companys VOR33 eHSCs lacks CD33 a protein that is expressed by AML blood cancer cells The companys eHSCs targeted therapies such as CARTs bispecific antibodies and antibodydrug conjugates provide treatment for blood cancers Vor Biopharma Inc has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases The company was incorporated in 2015 and is headquartered in Cambridge Massachusetts